Block GmbH Centre for Living Cell Therapy The fresh cell therapy/stem cell therapy is always a full body treatment. The improvement of the function of individual organs also affects all other organs positively. By: VIPiChannel … Continue reading →

SINGAPORE: Australia-based stem cell therapy firm Mesoblast has announced plans to accelerate commercial manufacturing operations in Singapore. This is to prepare for new product launches in the United States and other major markets over the next couple of years. Its existing operations in Singapore include making stem cell products for clinical trials under its contract with its partner, pharmaceutical company Lonza. One of its key products still awaiting full approval is Prochymal, which Mesoblast says can help to more than double the survival rate of patients suffering from complications after receiving tissue transplants from donors -- known as graft versus host disease. The global stem cell market is expected to grow at an average annual rate of 12 per cent between 2011 and 2016 to reach more than S$8 billion by 2016. Mesoblast said commercial manufacturing requires a much larger capacity and operations must be scaled-up to meet regulatory demands. Silviu Itescu, chief executive at Mesoblast, said: "We are now in a phase of making more investments in order to get our processes to commercial scale. That anticipates successful commercial launches. "If we're successful in that over the next 18-24 months, then we're going to leverage the investment in our … Continue reading →

Washington, DC (PRWEB) May 28, 2014 Catherine M. Bollard, MBChB, MD, director of Childrens National Health Systems Program for Cell Enhancement and Technologies for Immunotherapy (CETI), and her team have performed the hospitals first treatment using T-cell therapy for a 6-month-old patient with congenital immune deficiency and a life-threatening virus infection. Not only does this therapy offer a potentially curative treatment for patients who have failed conventional therapies for infections and cancer, the procedure sets the stage for avoiding potentially toxic drugs which can ultimately reduce inpatient stays and medical costs. Its extremely important, offering a novel therapeutic thats not available at the majority of hospitals worldwide, said Dr. Bollard, a member of the Division of the Blood and Marrow Transplantation and senior scientist at Childrens Nationals Center for Cancer and Immunology Research at Childrens Research Institute. She is also the Principal Investigator and the Sheik Zayed Institute for Pediatric Surgical Innovation. Childrens National is one of the few hospitals in the world to offer cellular therapy to treat life-threatening infections in patients with immune deficiencies as well as preventing or treating relapse in children with cancer. Cellular therapy uses the bodys own immune system to fight cancer and/or infections. … Continue reading →

(PRWEB) May 26, 2014 The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW). Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market. http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html Early buyers will receive 10% customization on report. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. Inquire before buying at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48. This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020. Download PDF brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=48. A number of factors such as increasing … Continue reading →

By Joel Ceausu, May 28th, 2014 An East End Montreal hospital is home to a new national network on regenerative medicine and cell therapy research. CellCAN will be based at Maisonneuve-Rosemont Hospital and directed by renowned cell therapy researcher Dr. Denis Claude Roy. The objective is to unite efforts of researchers, clinicians, funders, industry, charities, government members, patient representatives and the public. Specifically, CellCAN will promote exchanges, cooperation, partnership development and innovation in regenerative medicine and cell therapy, explained Roy. As the hub of a network of cell therapy centers and labs in Toronto, Ottawa, Quebec City, Edmonton, and Vancouver, CellCAN will propel Canadian stem cell research and clinical development forward thanks to a $3 million grant over four years. Discoveries in stem cell research make their way to clinical trials bringing researchers closer to new treatments for patients with cancer, diabetes, cardiovascular and ocular diseases, neurological and blood disorders and other health issues. Regenerative cell therapies have almost unlimited possibilities, said Roy, director of the cellular therapy laboratory at Maisonneuve-Rosemonts research centre. This will transform the nature of medicine and have significant impact on our health care systems. The Universit de Montral-affiliated hospital in Rosemont is an internationally recognized … Continue reading →